Risk! Evidence! Guidelines! Fine tuning type 2 diabetes management in adults
What tools are available to assess cardiovascular risk in adult type 2 diabetes?
(Episode 2)
What’s in it for me?
We value your feedback and would appreciate your help in shaping future podcasts. After listening, click here to complete the evaluation form.
Please download your CPD accreditation certificate by clicking here and record your learning reflections to support your annual professional revalidation.
GP and Director. Croydon GP Collaborative, Croydon and the James O'Riordan Medical Centre, Sutton
GP with a specialist interest in cardiology
This CPD-accredited podcast will cover the following topics:
- The link between type 2 diabetes and cardiovascular risk
- The relevance of using QRISK tools in primary care to calculate and predict cardiovascular risk early in Type 2 Diabetes Progression
- How clinical trials such as cardiovascular outcome trials help us understand the potential benefits and harms of newer glucose-lowering medications and discuss these with patients
- Tips to meaningfully interpret and effectively communicate cardiovascular risk to your patients
For full prescribing and safety information in relation to individual SGLT2 inhibitors, please refer to relevant summary of product characteristics as SGLT2 inhibitor indications vary.
Abbreviations used in this podcast:
BMI, body mass index; CKD, chronic kidney disease; GLP-1, glucagon-like-peptide-1; HCP, healthcare professional; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SGLT2, sodium-glucose cotransporter-2; SLE, systemic lupus erythematosus
Podcasts 1 and 3 of this series will cover the following topics:
- The evolution in the evidence that currently guides the management of adults living with type 2 diabetes
- The importance of moving away from glucocentric approach to Type 2 Diabetes management thinking beyond reductions: The role of the UK Prospective Diabetes Study(UKPDS). The significance of the EMPA-REG OUTCOME trial in holistic management of Type 2 Diabetes
- The role of primary care in the early management of CRM conditions, key takeaways from the NICE Type 2 Diabetes guidelines and early initiation of SGLT2i therapy in primary care
How has the management of adult type 2 diabetes changed in recent decades?
Speaker: Professor Mike Cummings
Early adoption in primary care of cardiorenal metabolic medicines in adult type 2 diabetes
Speaker: Shivani Patel
PC-GB-111730 | July 2025
The content on this website is in relation to adult patients.
Empagliflozin is not recommended in severe hepatic impairment, breastfeeding, Type 1 diabetes and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. Empagliflozin should be avoided in pregnancy.
Please consult the SmPC for full details regarding adverse events, monitoring requirements and interactions prior to prescribing JARDIANCE®.
- JARDIANCE® (empagliflozin) UK Summary of Product Characteristics (SmPC). Available at:
http://www.medicines.org.uk/emc/medicine/28973.
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes1
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
PC-GB-109995 V4 | October 2025